Importantly, FXR agonists have not been shown to increase the expression of drug efflux transporters, such as BCRP and P-gp, making it a more interesting approach to inducing anticancer drug accumulation to cancer cells than the use of PXR agonists. This evidence concerns the gene NR1I2 and cancer.